Project Grant R37CA288502
Award Date
9/1/24
Completion Date
8/31/29
Dollars Obligated
$1.2M
Federal Agency
National Cancer Institute
Federal Grant Program
93.353
Assistance Type
Project Grant
Place of Performance
Miami, FL 33136, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353) supports research to investigate how race and genetic ancestry impact the tumor immune microenvironment and response to immunotherapy in breast cancer patients. The $369,354 award will fund a 2-year project that utilizes population-based cancer registry data and an existing breast cancer clinical trial to examine genetic ancestry, race/ethnicity,...
This federal Project Grant award, valued at $352,141.00 and issued by the National Cancer Institute under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353), aims to address cancer health disparities in Black residents of metropolitan Detroit. The primary objectives are to: 1) Identify ancestry-specific genetic regulators of macrophage function and response to anti-HER2 antibody therapy that potentially underlie racial differences in response to this targeted...
This Project Grant award of $730,398.00 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the Sloan-Kettering Institute for Cancer Research aims to comprehensively characterize the lung cancer genomic landscape in patients of African ancestry. The key products and services to be delivered under this 5-year award include: Identifying and validating genomic differences between lung cancer patients of African and European ancestry, with a focus on drug targetable and...
This federal Project Grant award, funded by the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), aims to investigate the biological mechanisms underlying racial disparities in head and neck cancer outcomes, particularly among Black patients. The $714,062 award, with a period of performance from April 2025 to March 2030, will be provided to the University of California, San Francisco (UCSF) to pursue two key objectives: 1) Developing a tailored RNA...
This $334,233 federal Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program supports a research project conducted by the University of South Carolina to examine disparities in cancer care and outcomes. The project aims to: Describe and compare patterns of novel targeted therapies for lung and colon cancer by race, socioeconomic status, and urban/rural designation, and their impact on survival disparities. Describe and...
This federal Project Grant award of $589,591 from the National Cancer Institute (NCI) under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353) aims to determine how social factors may explain poorer survival outcomes for Black and Hispanic patients with Hodgkin lymphoma (HL). The 5-year study at the University of Florida will: Examine differences in the receipt and quality of HL treatment for initial diagnosis and relapse. Examine the receipt and quality of...
This federal Project Grant award from the National Cancer Institute (NCI) under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353) provides $1,131,820 in funding for a 5-year research project focused on characterizing and predicting toxicities and health-related quality of life outcomes for diverse individuals receiving immune checkpoint inhibitor cancer treatments. The research, led by the University of Miami, aims to: 1) assess toxicities and health-related quality...
This $432,304 federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), supports a research project titled "Enhanced Cancer Risk Predictions in Underrepresented Populations through Robust Multi-Source Data Integration." The project aims to develop novel data integration methods to enhance cancer risk prediction models, particularly for Black and Hispanic populations who face disproportionate cancer...
This $2,372,456 federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) supports a multi-institutional research collaboration led by Memorial Sloan Kettering Cancer Center to leverage observational (real-world) data to advance precision oncology. The key products/services to be delivered include: Overcoming methodological barriers in analyzing observational clinico-genomic data (Project 1) Addressing the role of...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $659,498.00 to Emory University to conduct research on racial disparities in the mechanisms of prostate cancer metastasis. The project aims to analyze differential pathway activity related to oxidative phosphorylation (OXPHOS) and FGFR3 signaling, and to determine the impact of perturbing these pathways on metastatic potential in African American prostate cancer models. The...